Analysts have reduced their price target for hVIVO from £0.21 to £0.17. They cite slower expected revenue growth and tightening profit margins as key factors behind the adjustment.
What's in the News
- hVIVO shared positive data from several newly developed human challenge models at major scientific conferences in October 2025, highlighting strong safety and tolerability profiles (Key Developments).
- The company's human Metapneumovirus (hMPV) challenge model demonstrated high infection rates and robust virology results. This model is now available for clinical trials (Key Developments).
- The introduction of the world's first commercially available Omicron (BA5) human challenge model emphasizes optimal dosing timing for post-exposure prophylaxis (Key Developments).
- Positive results were reported from a new Respiratory Syncytial Virus B (RSV B) model, which forms a key part of a comprehensive vaccine efficacy testing platform (Key Developments).
- hVIVO provided revenue guidance for 2026, projecting high-single digit growth driven by diversified services and normalization of Clinical Trial (HCT) activity (Key Developments).
Valuation Changes
- Fair Value: Decreased from £0.21 to £0.17, indicating a lowered analyst valuation.
- Discount Rate: Increased from 7.88% to 8.92%, reflecting higher perceived risk.
- Revenue Growth: Declined significantly from 4.48% to 2.16% projected annual growth.
- Net Profit Margin: Fell from 6.08% to 4.47%, showing expectations of reduced profitability.
- Future P/E: More than doubled from 30.39x to 60.42x, which suggests a higher valuation relative to future earnings.
Have other thoughts on hVIVO?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.